Theme: Frontiers in Cell and Gene Therapy: From Bench to Bedside

Cell Therapy 2016

Cell Therapy 2016

Track-1 Cell Therapy

Cell therapy as performed by alternative medicine practitioners is very different from the controlled research done by conventional stem cell medical researchers. Alternative practitioners refer to their form of cell therapy by several other different names including xenotransplanttherapy, glandular therapy, and fresh cell therapy. Proponents of cell therapy claim that it has been used successfully to rebuild damaged cartilage in joints, repair spinal cord injuries,strengthen a weakened immune system, treat autoimmune diseases such as AIDS, and help patients with neurological disorders such asAlzheimer's disease, Parkinson's disease and epilepsy.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 5th Cell & Gene Therapy Conference 19-21 May 2016 (San Antonio, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

Track-2 Gene therapy

Gene therapy and cell therapy are overlapping fields of biomedical research with the goals of repairing the direct cause of genetic diseases in the DNA or cellular population, respectively. The development of suitable gene therapy treatments for many genetic diseases and some acquired diseases has encountered many challenges and uncovered new insights into gene interactions and regulation. Further development often involves uncovering basic scientific knowledge of the affected tissues, cells, and genes, as well as redesigning vectors, formulations, and regulatory cassettes for the genes. Cell therapy is expanding its repertoire of cell types for administration. Cell therapy treatment strategies include isolation and transfer of specific stem cell populations, administration of effector cells, and induction of mature cells to become pluripotent cells, and reprogramming of mature cells.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 5th Cell & Gene Therapy Conference 19-21 May 2016 (San Antonio, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

Track-3 Cell and gene therapy products:

Articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer to a human recipient. Gene therapies are novel and complex products that can offer unique challenges in product development. Hence, ongoing communication between the FDA and stakeholders is essential to meet these challenges. Gene therapy products are being developed around the world, the FDA is engaged in a number of international harmonization activities in this area.

Examples: Musculoskeletal tissue, skin, ocular tissue, human heart valves; vascular graft, dura mater, reproductive tissue/cells, Stem/progenitor cells ,somatic cells, Cells transduced with gene therapy vectors , Combination products (e.g., cells or tissue + device)

Related conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31October – 02November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

Track-4 Cellular therapy:

Cellular therapy, also called live cell therapy, cellular suspensions, glandular therapy, fresh cell therapy, sick cell therapy, embryonic cell therapy, and organotherapy - refers to various procedures in which processed tissue from animal embryos, fetuses or organs, is injected or taken orally. Products are obtained from specific organs or tissues said to correspond with the unhealthy organs or tissues of the recipient. Proponents claim that the recipient's body automatically transports the injected cells to the target organs, where they supposedly strengthen them and regenerate their structure. The organs and glands used in cell treatment include brain, pituitary, thyroid, adrenals, thymus, liver, kidney, pancreas, spleen, heart, ovary, testis, and parotid. Several different types of cell or cell extract can be given simultaneously - some practitioners routinely give up to 20 or more at once.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31October – 02November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); Adaptive T cell Therapy 27-28 April, 2016 ( Boston, MA); 2ND International Congress on Stem Cell and Cellular Therapies 15-18 October 2015 (Antalya, Turkey); Cellular Therapy Today 9-12 September 2015 (Manchester,UK); The 2nd Gene and Immunotherapy Conference in Vietnam 25-26 September 2015 (Ho Chi Minh City, Vietnam); Cell and Gene Therapy  World 25- 16 January 2016 (Washington DC).

Track-5 Cancer gene therapy:

Cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer. Many cancer therapies have been approved by the Food and Drug Administration (FDA) to treat specific types of cancer. The development of targeted therapies requires the identification of good targets that is, targets that play a key role in cancer cell growth and survival. One approach to identify potential targets is to compare the amounts of individual proteins in cancer cells with those in normal cells.  Proteins that are present in cancer cells but not normal cells or that are more abundant in cancer cells would be potential targets, especially if they are known to be involved in cell growth or survival.

Related Conferences: International Conference on Cervical Cancer, 22-23 September, 2016 (Vienna, Austria); 6th World Congress on Cancer Therapy, 01-03 December, 2016 (Baltimore, USA); 13th Global Summit on Cancer Therapy 17-19 October, 2016 (Dubai, UAE); International Conference on Pancreatic and Colorectal Cancer, 29-30 March, 2016 (Atlanta, USA); Global Summit on Melanoma And Carcinoma, 14-15 July, 2016 (Brisbane, Australia); Chromatin and Epigenetic in Cancer ( Atlanta, Georgia); Advances in Ovarian Cancer Research: Exploiting Vulnerabilities (Orlando, Florida); Advance in Breast Cancer Research ( Washington, DC); Advances in Pediatric Cancer Research (Florida);  New Horizons in Cancer Research Conference (Sanghai, China).

Track-6 Nano therapy:

Nano Therapy may be defined as the monitoring, repair, construction and control of human biological systems at the molecular level, using engineered nanodevices and nanostructures. Basic nanostructured materials, engineered enzymes, and the many products of biotechnology will be enormously useful in near-term medical applications. However, the full promise of nanomedicine is unlikely to arrive until after the development of precisely controlled or programmable medical nanomachines and nanorobots.

Related Conferences: 2nd International Conference and Expo On Computer Graphics & Animation, 21-22 September, 2015 (San Antonio, USA); 4th International Conference and Exhibition On Biosensors & Bioelectronics, 28-30 September, 2015 (Atlanta, USA); 3rd International Conference and Exhibition On Mechanical & Aerospace Engineering, 05-07 October, 2015 (San Antonio, USA); Global Summit on Electronics and Electrical Engineering, 03-05 November, 2015 (Valencia, Spain); International Conference on Medical Devices, 21-22 September, 2015(Florida, USA); Nanotechnologies in Drug Delivery  Congress 27-28 April 2016  (London, UK); 4th Annual Symposium on Nanobiotechnology 7-8 October 2015 (Germany); Radiation Damage in biomolecular Systems: Nanoscale Insights into Ion-Beam Cancer Therapy 20-24 may 2016 (Germany); 5th International Conference Nanomaterials: Applications & Properties 2015, 16-23 September 2015 (Lviv, Ukraine); International Conference on Micro-and Nano-Engineering 2015, 21-24 September2015, (The Hague, Netherlands).

Track-7 Skin cell therapy:

Stem cells have newly become a huge catchphrase in the skincare biosphere. Skincare specialists are not using embryonic stem cells; it is impossible to integrate live materials into a skincare product.  Instead, scientists are creating products with specialized peptides and enzymes or plant stem cells which, when applied topically on the surface, help to protect the human skin stem cells from damage and deterioration or stimulate the skins own stem cells. Currently, the technique is mainly used to save the lives of patients who have third degree burns over very large areas of their bodies

Related Conferences: 8th Indo Global Summit And Expo On Vaccines, Therapeutics & Healthcare, 02-04 November, 2015, (Hyderabad, India); 4th International Conference On Clinical Microbiology And Microbial Genomics, 05-07 October, 2015 (Philadelphia, USA); International Conference On Psoriasis, 28-30 November, 2016 (Baltimore, USA); 6th International Conference On Clinical And Experimental Dermatology, 05-07, May, 2016 (Chicago, USA); 11th Global Dermatologists Meeting, 14-16, November, 2016 (Dubai, UAE); 2nd International Conference And Exhibition On Cosmetic Dermatology &Haircare, 05-06, December, 2016 (Seattle, USA); Adaptive T cell Therapy 27-28 April, 2016 ( Boston, MA), 2ND International Congress on Stem Cell and Cellular Therapies 15-18 October 2015 (Antalya, Turkey); Cellular Therapy Today 9-12 September 2015 (Manchester,UK); Cell and Gene Therapy  World 25- 16 January 2016 (Washington DC). 

Track-8 HIV gene therapy:

Highly active antiretroviral therapy dramatically improves survival in HIV-infected patients. However, persistence of HIV in reservoirs has necessitated lifelong treatment that can be complicated by cumulative toxicities, incomplete immune restoration, and the emergence of drug-resistant escape mutants. Cell and gene therapies offer the promise of preventing progressive HIV infection by interfering with HIV replication in the absence of chronic antiviral therapy.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 5th Cell & Gene Therapy Conference 19-21 May 2016 (San Antonio, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

Track-9 Diabetes for gene therapy:

Cell therapy approaches for this disease are focused on developing the most efficient methods for the isolation of pancreas beta cells or appropriate stem cells, appropriate location for cell transplant, and improvement of their survival upon infusion. Alternatively, gene and cell therapy scientists are developing methods to reprogram some of the other cells of the pancreas to secrete insulin. Currently ongoing clinical trials using these gene and cell therapy strategies hold promise for improved treatments of type I diabetes in the future. The first gene therapy approach to diabetes was put forward shortly after the cloning of the insulin gene. It was proposed that non-insulin producing cells could be made into insulin-producing cells using a suitable promoter and insulin gene construct, and that these substitute cells could restore insulin production in type 1 and some type 2 diabetics. 

Related Conferences: International Conference on Synthetic Biology, September 28-30, 2015 (Houston, USA); 6th World Congress on Biotechnology, October 05-07, 2015 (New Delhi, India); 3rd International Conference on Genomics & Pharmacogenomics, September 21-23, 2015 (San Antonio, USA); World Bio Summit & Expo, November 02-04, 2015 (Dubai, UAE); International Conference on Genetic Counselling And Genomic Medicine, August 11-12, 2016 (Birmingham, UK); Cell Symposia: Stem Cell Epigenetics 20-22 September 2015 (Barcelona, Spain); EMBO Conference The DNA damage response in cell physiology and disease 5-9 October 2015 (Cape Sounio, Greece); EMBO Conference Nuclear structure and dynamics 7-11 October 2015 (L'Isle-sur-la-Sorgue, France); CSH Asia Mitochondria 12-16 October 2015 (Cold Spring Harbour, New York); ABCAM Chromatin Structure and Function 16-19 November 2015 (Grand Cayman Island).

Track-10 Viral gene therapy:

Converting a virus into a vector The viral life cycle can be divided into two temporally distinct phases: infection and replication. For gene therapy to be successful, an appropriate amount of a therapeutic gene must be delivered into the target tissue without substantial toxicity. Each viral vector system is characterized by an inherent set of properties that affect its suitability for specific gene therapy applications. For some disorders, longterm expression from a relatively small proportion of cells would be sufficient (for example, genetic disorders), whereas other pathologies might require high, but transient, gene expression. For example, gene therapies designed to interfere with a viral infectious process or inhibit the growth of cancer cells by reconstitution of inactivated tumor suppressor genes may require gene transfer into a large fraction of the abnormal cells.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 5th Cell & Gene Therapy Conference 19-21 May 2016 (San Antonio, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

Track-11 Stem cell therapies:

Stem cells have tremendous promise to help us understand and treat a range of diseases, injuries and other health-related conditions. Their potential is evident in the use of blood stem cells to treat diseases of the blood, a therapy that has saved the lives of thousands of children with leukaemia; and can be seen in the use of stem cells for tissue grafts to treat diseases or injury to the bone, skin and surface of the eye. Some bone, skin and corneal (eye) injuries and diseases can be treated by grafting or implanting tissues, and the healing process relies on stem cells within this implanted tissue.  

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); World Stem Cell Summit 10-12 December (Atlanta, Georgia); 2nd International Conference on Stem Cell and Cellular Therapies 15-18 October (Antalya, Turkey); Stem Cell 2016 Summit 27-29 April (Boston, MA); 3rd International Annual Conference of the German Stem Cell Network 9-11 September (Frankfurt); Stem cell Epigenetics 20-22 September (Stiges, Spain).

Track-12 Stem cell preservation:

The ability to preserve the cells is critical to their clinical application. It improves patient access to therapies by increasing the genetic diversity of cells available. In addition, the ability to preserve cells improves the "manufacturability" of a cell therapy product by permitting the cells to be stored until the patient is ready for administration of the therapy, permitting inventory control of products, and improving management of staffing at cell therapy facilities. Finally, the ability to preserve cell therapies improves the safety of cell therapy products by extending the shelf life of a product and permitting completion of safety and quality control testing before release of the product for use. preservation permits coordination between the manufacture of the therapy and patient care regimes.

Related conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31October – 02November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

Track-13 Stem cell products:

The global stem cell, Stem cell products market will grow from about $5.6 billion in 2013 to nearly $10.6 billion in 2018, registering a compound annual growth rate (CAGR) of 13.6% from 2013 through 2018.This track discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analysed by the most important national markets

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 5th Cell & Gene Therapy Conference 19-21 May 2016 (San Antonio, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium).

Track-14 Genetically inherited diseases:

A genetic disease is any disease that is caused by an abnormality in an individual's genome, the person's entire genetic makeup. The abnormality can range from minuscule to major -- from a discrete mutation in a single base in the DNA of a single gene to a gross chromosome abnormality involving the addition or subtraction of an entire chromosome or set of chromosomes. Most genetic diseases are the direct result of a mutation in one gene. However, one of the most difficult problems ahead is to find out how genes contribute to diseases that have a complex pattern of inheritance, such as in the cases of diabetes, asthma, cancer and mental illness. In all these cases, no one gene has the yes/no power to say whether a person has a disease or not. It is likely that more than one mutation is required before the disease is manifest, and a number of genes may each make a subtle contribution to a person's susceptibility to a disease; genes may also affect how a person reacts to environmental factors.

Related Conferences: International Conference on Synthetic Biology, September 28-30, 2015 (Houston, USA); 6th World Congress on Biotechnology, October 05-07, 2015 (New Delhi, India); 3rd International Conference on Genomics & Pharmacogenomics, September 21-23, 2015 (San Antonio, USA); World Bio Summit & Expo, November 02-04, 2015 (Dubai, UAE); International Conference on Genetic Counselling And Genomic Medicine, August 11-12, 2016 (Birmingham, UK); Cell Symposia: Stem Cell Epigenetics 20-22 September 2015 (Barcelona, Spain); EMBO Conference The DNA damage response in cell physiology and disease 5-9 October 2015 (Cape Sounio, Greece); EMBO Conference Nuclear structure and dynamics 7-11 October 2015 (L'Isle-sur-la-Sorgue, France); CSH Asia Mitochondria 12-16 October 2015 (Cold Spring Harbour, New York); ABCAM Chromatin Structure and Function 16-19 November 2015 (Grand Cayman Island).

Track-15 Plant stem cells:

Plants have emerged as powerful production platforms for the expression of fully functional recombinant mammalian proteins. These expression systems have demonstrated the ability to produce complex glycoproteins in a cost-efficient manner at large scale. The full realization of the therapeutic potential of stem cells has only recently come into the forefront of regenerative medicine. Stem cells are unprogrammed cells that can differentiate into cells with specific functions. Regenerative therapies are used to stimulate healing and might be used in the future to treat various kinds of diseases. Regenerative medicine will result in an extended healthy life span. A fresh apple is a symbol for beautiful skin. Hair greying for example could be shown to result from the fact that the melanocyte stem cells in the hair follicle have died off.

Related Conferences: Global Summit on Plant Science, 21-23 September, 2015, (San Antonio, USA); Global Summit on Herbals & Natural Remedies, 26-27 October, 2015, (Chicago, USA); 8th Indo Global Summit And Expo On Vaccines, Therapeutics & Healthcare, 02-04, November, 2015 (Hyderabad, India); 4th International Conference and Exhibition on Probiotics, Functional And Baby Foods 03-05, November, 2015 (Valencia, Spain); 2nd International Conference on Green Energy & Expo, 28-30 November, 2016 (Chicago, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine 18-19 September (Kansas City, Missouri); Keystone Symposia: Molecular and Cellular Basis of Growth and Regeneration 10-11 January (Breckenridge, Colorado); Keystone Symposia – Stem Cells and Regeneration in the Digestive Organs 13-17 ,March (Keystone, Colorado); World Conference on Regenerative Medicine 21-23 October (Leipzig, Germany); 2nd International Congress on Stem Cell and Cellular Therapies 15-18 October (Antalya, Turkey).

Track-16 Plant stem cell rejuvenation:

As plants cannot escape from danger by running or taking flight, they need a special mechanism to withstand environmental stress. What empowers them to withstand harsh attacks and preserve life is the stem cell. According to Wikipedia, “plant stem cells never undergo the aging process but constantly create new specialized and unspecialized cells, and they have the potential to grow into any organ, tissue, or cell in the body.” The everlasting life is due to the hormones auxin and gibberellin. British scientists found that plant stem cells were much more sensitive to DNA damage than other cells. And once they sense damage, they trigger death of these cells.

Rejuvenate with Plant Stem Cells

Detoxify and release toxins on a cellular level.
Nourish your body with vital nutrients.
Regenerate your cells and diminish the effects of aging.

Related Conferences: Global Summit on Plant Science, 21-23 September, 2015, (San Antonio, USA); Global Summit on Herbals & Natural Remedies, 26-27 October, 2015, (Chicago, USA); 8th Indo Global Summit And Expo On Vaccines, Therapeutics & Healthcare, 02-04, November, 2015 (Hyderabad, India); 4th International Conference and Exhibition on Probiotics, Functional And Baby Foods 03-05, November, 2015 (Valencia, Spain); 2nd International Conference on Green Energy & Expo, 28-30 November, 2016 (Chicago, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine 18-19 September (Kansas City, Missouri); Keystone Symposia: Molecular and Cellular Basis of Growth and Regeneration 10-11 January (Breckenridge, Colorado); Keystone Symposia – Stem Cells and Regeneration in the Digestive Organs 13-17 ,March (Keystone, Colorado); World Conference on Regenerative Medicine 21-23 October (Leipzig, Germany); 2nd International Congress on Stem Cell and Cellular Therapies 15-18 October (Antalya, Turkey).

Track-17 Clinical trials in cell and gene therapy:

clinical trial is a research study that seeks to determine if a treatment is safe and effective. Advancing new cell and gene therapies (CGTs) from the laboratory into early-phase clinical trials has proven to be a complex task even for experienced investigators. Due to the wide variety of CGT products and their potential applications, a case-by-case assessment is warranted for the design of each clinical trial.

Objectives: Determine the pharmacokinetics of this regimen by the persistence of modified T cells in the blood of these patients, Evaluate the immunogenicity of murine sequences in chimeric anti-CEA Ig TCR, Assess immunologic parameters which correlate with the efficacy of this regimen in these patients, Evaluate, in a preliminary manner, the efficacy of this regimen in patients with CEA bearing tumours.

Related Conferences: 4th International Summit On GMP, GCP & Quality Control, 26-28 October, 2015 (Hyderabad, India); 3rd International Conference on Clinical Pharmacy, 07-09 December, 2015 (Atlanta, USA); Pharmaceutical Summit and Expo, 08-10 October, 2015 (New Delhi, India); 3rd International Conference and Exhibition On Pharmacognosy, Phytochemistry& Natural Products, 26-28 October, 2015 (Hyderabad, India); Patient-Centered Clinical Trials 2015 19-20 October 2015 (Le Méridien, Philadelphia); Quantitative Systems Pharmacology 20-22 October 2015 (Boston, MA); Clinical Development and Commercialization of Antibacterial  22-23 September 2015 (Boston, MA); Summit for Clinical Ops Executives 23-25 February 2016( Miami, FL); Clinical IT Strategy and Governance 23-25 February 2016 (Miami, FL).

Track-18 Molecular epigenetics:

Epigenetics is the study of heritable changes in the phenotype of a cell or organism that are not caused by its genotype. The molecular basis of an epigenetic profile arises from covalent modifications of protein and DNA components of chromatin. The epigenetic profile of a cell often dictates cell fate, as well as mammalian development, aging and disease. Epigenetics has evolved to become the science that explains how the differences in the patterns of gene expression in diverse cells or tissues are executed and inherited.

Related Conferences: International Conference on Synthetic Biology, September 28-30, 2015 (Houston, USA); 6th World Congress on Biotechnology, October 05-07, 2015 (New Delhi, India); 3rd International Conference on Genomics & Pharmacogenomics, September 21-23, 2015 (San Antonio, USA); World Bio Summit & Expo, November 02-04, 2015 (Dubai, UAE); International Conference on Genetic Counselling And Genomic Medicine, August 11-12, 2016 (Birmingham, UK); Cell Symposia: Stem Cell Epigenetics 20-22 September 2015 (Barcelona, Spain); EMBO Conference The DNA damage response in cell physiology and disease 5-9 October 2015 (Cape Sounio, Greece); EMBO Conference Nuclear structure and dynamics 7-11 October 2015 (L'Isle-sur-la-Sorgue, France); CSH Asia Mitochondria 12-16 October 2015 (Cold Spring Harbour, New York); ABCAM Chromatin Structure and Function 16-19 November 2015 (Grand Cayman Island).

Track-19 Bioengineering therapeutics:

The goals of bioengineering strategies for targeted cancer therapies are (1) to deliver a high dose of an anticancer drug directly to a cancer tumour, (2) to enhance drug uptake by malignant cells, and (3) to minimize drug uptake by non-malignant cells. In ESRD micro electro mechanical systems and nanotechnology to create components such as robust silicon Nano pore filters that mimic natural kidney structure for high-efficiency toxin clearance. It also uses tissue engineering to build a miniature bioreactor in which immune-isolated human-derived renal cells perform key functions, such as reabsorption of water and salts. In drug delivery for a leading cause of blindness, photo-etching fabrication techniques from the microchip industry to create thin-film and planar micro devices (dimensions in millionths of meters) with protective medication reservoirs and nanopores (measured in billionths of meters) for insertion in the back of the eye to deliver sustained doses of drug across protective retinal epithelial tissues over the course of several months.

Related Conferences: International Conference On Protein Engineering, 26-28 October, 2015 (Chicago, USA); 4th International Conference and Exhibition on Biometrics & Biostatistics, 16-18 November, 2015 (San Antonio, USA); 4th International Conference and Exhibition On Biosensors & Bioelectronics, 28-30 September, 2015 (Atlanta, USA); International Conference and Business Expo On Wireless Communication & Network, 21-23 September, 2015 (Baltimore, USA); Global Summit on Electronics And Electrical Engineering, 03-05 November, 2015 (Valencia, Spain); International Conference on Medical Devices, 21-22 September, 2015 (Florida, USA); 2015 International Conference on Manufacturing and Optimization 15-16 September 2015(Singapore); Imaging: Recent Advances and Biomedical Applications 30th September (London, United Kingdom); Singapore Health & Biomedical Congress 2015 2-3 October 2015 (Singapore ); VECCOMAS Thematic Conferences on Computational Vision and Medical Image Processing Tenerife 19-21 October 2015(Spain); Protein & Antibody Engineering Summit 2-6 November 2015(Lisbon, Portugal).

Track-20 Advanced gene therapy

Advanced therapies are different from conventional medicines, which are made from chemicals or proteins. Gene-therapy medicines: these contain genes that lead to a therapeutic effect. They work by inserting 'recombinant' genes into cells, usually to treat a variety of diseases, including genetic disorders, cancer or long-term diseases. Somatic-cell therapy medicines: these contain cells or tissues that have been manipulated to change their biological characteristics. Advanced Cell & Gene Therapy provides guidance in process development, GMP/GTP manufacturing, regulatory affairs, due diligence and strategy, specializing in cell therapy, gene therapy, and tissue-engineered regenerative medicine products.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31October – 02November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States),; Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium).

Track-21 Ethical issues of therapies:

Gene therapy involves making changes to the body’s set of basic instructions, it raises many unique ethical concerns. Current gene therapy research has focused on treating individuals by targeting the therapy to body cells such as bone marrow or blood cells. This type of gene therapy cannot be passed on to a person’s children. Gene therapy could be targeted to egg and sperm cells. Stem Cell Research offers great promise for understanding basic mechanisms of human development and differentiation, as well as the hope for new treatments for diseases such as diabetes, spinal cord injury, Parkinson’s disease, and myocardial infarction. Pluripotent stem cells perpetuate themselves in culture and can differentiate into all types of specialized cells. Scientists plan to differentiate pluripotent cells into specialized cells that could be used for transplantation.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31October – 02November 2016 (Valencia, Spain); International Conference On Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

OMICS International welcomes you to attend the 5th International Conference and Exhibition on Cell & Gene Therapy during May 19-21, 2016 at San Antonio, USA. We cordially invite all the participants who are interested in sharing their knowledge and research in the arena of Cell & Gene Therapy.

Cell and Gene Therapy Conference is to ameliorate the knowledge, awareness, and education on cell and gene therapy leading to the discovery of genetic and cellular therapies which aid to alleviate the human disease as it is the most significant emerging technology in the eyes of Medical, Biotechnology, Pharmaceuticals and Academia. Cell and Gene Therapy Conference 2016 is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists.

Cell Therapy Conferences will provide a perfect platform to all the Doctors, Researchers Business Delegates and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere.

Gene Therapy Conferences strategic astuteness is to be an event for bringing together Scientists, Physicians, International mix of leading Universities, Cell Gene Therapy Institutions to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

This three-day Gene Therapy Event will address key issues concerning cell and gene therapy in the broader context of cellular and genetic disorder. Organized around daily themes, the Conference focuses on moving from present knowledge to future solutions

Global markets for stem cells by BCC Research (2012), cited by Ministry of Food and Drug Safety, predicted the global market size of stem cell therapy product would be 6.6 billion dollars in 2016 and grow 11.7% on average every year. Currently, US's stem cell therapy product occupying the biggest market share amounts to 1.3 billion dollars and Europe's is 872 million dollars. US's stem cell therapy product market is predicted to have an average annual growth rate of 11.5% (2.3 billion dollars in 2016), and Europe's is 10.9% (1.5 billion dollars in 2016).

OMICS International Organises 300+ International Conferences Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

The previous conferences on Cell & Gene Therapy which were held at Chicago, USA and London, UK have explained Research & Advancements in Cell and Gene Therapy, gained so much of interest for eminent scientists all over the world in the field of Cell & Gene Therapy. Now it is the time for the 5th International Conference and Exhibition on Cell & Gene Therapy to address Frontiers in Cell and Gene Therapy: From Bench to Bedside which will be held from May 19-21, 2016 at San Antonio, USA.

Target Audience

Cell and Gene Therapy Students, Scientists

Cell and Gene Therapy Researchers

Cell and Gene Therapy Faculty

Cell and Gene Therapy Associations and Societies

Cell and Gene Therapy physicians

Cell and Gene Therapy advanced practice registered nurses,

Allied health professionals in the fields of Cell and Gene Therapy,hematology, oncology, neurology, family medicine and internal medicine.

Stem Cell Students, Scientists

Stem Cell Researchers

Stem Cell Faculty

Stem Cell Associations and Societies

Business Entrepreneurs

Training Institutes

Software developing companies

Importance & Scope:

Scope: The Scope of the conference is to gather all the Doctors, Researchers, Business Delegates and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere. This Cell and Gene Therapy Conference is the premier event focusing on understanding individual and organizational behaviour and decision-making related to genetics and molecular biology, biotechnology, pharmaceuticals, medicals and academia.

Importance: Conference on Cell & Gene Therapy is a much celebrated conference which basically deals with the latest research and developments in the sphere of Cell and molecular biology. This Conference will provide a perfect platform to all the International mix of leading Research Scholars, and Scientists achieved eminence in their field of study, research academicians from the universities and research institutions, industrial research professionals and business associates along with Ph.D. Students to come and inform all the attendees about the latest scientific advancements on the respective sphere.

Why San Antonio, USA?

San Antonio officially the City of San Antonio, is the seventh most populated city in the United States of America and the second most populated city in the state of Texas, with a population of 1,409,019. It was the fastest growing of the top 10 largest cities in the United States from 2000 to 2010, and the second from 1990 to 2000. The city is located in the American Southwest, the south–central part of Texas, and the southwestern corner of an urban region known as the Texas Triangle.

San Antonio hosts over 100,000 students in its 31 higher-education institutions. Publicly supported schools include the University of Texas Health Science Center at San Antonio, the University of Texas at San Antonio, Texas A&M University–San Antonio, and the Alamo Community College District. The University of Texas at San Antonio is San Antonio's largest university

Members Associated with Cell Therapy:

 

Figure: Members Associated

Top Major Societies Associated with Cell and Gene Therapy

  • British Society and Gene and Cell Therapy
  • American Society of Gene and Cell Therapy (ASGCT)
  • Australasian Gene Therapy Society (AGTS)
  • Austrian Network for Gene Therapy
  • British Society of Gene Therapy (BSGT)
  • European Society of Gene and Cell Therapy (ESGCT)
  • Finnish Gene Therapy Society (FGTS)
  • German Gene Therapy Society (DGGT)
  • International Society for Cancer Gene Therapy (ISCGT)
  • Irish Society for Gene & Cell Therapy (ISGCT)
  • Israeli Society of Gene & Cell Therapy (ISGCT)
  • Japan Society of Gene Therapy (JSGT)
  • Korean Society of Gene and Cell Therapy (KSGCT)
  • Netherlands Society of Gene and Cell Therapy (NVGCT)
  • Société Francophone de ThérapieCellulaire et  Génique (SFTCG)
  • Spanish Society of Gene and Cell Therapy (SETGyC)
  • Swedish Society for Gene and Cell Therapy (SSGCT)
  • Turkish Society of Gene & Cell Therapy (TSGCT)

Figure: Industries Associated with Cellular Therapies

Figure: Companies

Top Research Institutes of Cell and Gene Therapy Globally

Figure: List of Research Institutes

Market Value on Cell and Gene Therapy:

The global stem cell therapy market is expected to reach $330 million by 2020, at a CAGR of 39.5% from 2015 to 2020

The global stem cell market in 2015is expected to be dominated by North America, followed by Asia-Pacific and Europe. However, Asia-Pacific market is expected to surpass North America by 2020, owing to the high number of ongoing research activities.

Autologous Stem Cell and Non-Stem Cell Based Therapies market is currently estimated as $650 million, including products of all application areas. This market is anticipated to reach $2.2 billion by 2017, growing at a CAGR of 21%. ACT has already been successful in the treatment of prostate cancer, skin burns, cosmetic surgeries, skin substitutes, wound healing, pressure ulcers, etc.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market, Revenue Forecast

Figure: Market Value

The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2014-2024. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades.

Products manufactured by the industry related cell therapy and its market Value:

Global markets for stem cells by BCC Research (2012), cited by Ministry of Food and Drug Safety, predicted the global market size of stem cell therapy product would be 6.6 billion dollars in 2016 and grow 11.7% on average every year. Currently, US's stem cell therapy product occupying the biggest market share amounts to 1.3 billion dollars and Europe's is 872 million dollars. US's stem cell therapy product market is predicted to have an average annual growth rate of 11.5% (2.3 billion dollars in 2016), and Europe's is 10.9% (1.5 billion dollars in 2016). Until August 1, 2013, three stem cell therapies has acquired a sale permit for domestic use in Korea: Hearticellgram-AMI by FCB-Phamicell (the world's first stem cell therapy product), Cartistem by Medipost (the world's first allogenous stem cell therapy product) and Cupistem by Anterogen. Besides, 24 medicines are undergoing clinical trial till January 1, 2013.

Global markets for stem cells therapy product

Figure: Fund Allotment to Cell and Gene Therapy

US$3 billion state taxpayer-funded institute for stem cell research, the California Institute for Regenerative Medicine. It hopes to provide $300 million a year. However, in June 6, 2006, there were delays in the implementation of the California program and it is believed that the delays will continue for the significant future.  On July 21, 2006, Governor Arnold Schwarzenegger (R-Calif.) authorized $150 million in loans to the Institute in an attempt to jump start the process of funding research.

Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic funding. The Series A financing is led by MPM Capital, with Fidelity Biosciences, ARCH Venture Partners, and Medtronic participating. Alongside the equity financing, Semma entered into an undisclosed agreement with Novartis Pharmaceuticals.

NIH provided US$ 258 Million in funding for three SF universities, and US$ 41 Million to SF start up firms through Small Business Innovation Research grant scheme.

 

Cell Therapy-2015

OMICS International Conferences successfully hosted its premier 4th International Conference and Exhibition on Cell & Gene Therapy during August 10-12, 2015 at Crowne Plaza London-Heathrow, London, United Kingdom.

The conference brought together a comprehensive range of the cell and gene therapy researchers, educators from research universities as well as representatives from industry and professional cell and gene therapy societies.

Cell Therapy-2015 is known for uplifting the future of cell and gene therapy and its allied areas by encouraging students and fellow researchers to present their work through poster presentations and young research forum. Students participated with great zeal and the best posters were awarded for their efforts and outstanding contribution to the cell and gene therapy research.

OMICS International Conferences wishes to acknowledge with its deep sincere gratitude to all the supporters from the Editorial Board Members of our Open Access Journals, Keynote speakers, Honorable guests, valuable speakers, poster presenters, students, delegates and special thanks to the media partners for their promotion to make this event a huge success.

This 4th International Conference and Exhibition on Cell & Gene Therapy based on the theme “Genomic therapies from base pairs to bedside” which covered the below scientific sessions like Cell and Gene Therapy: Potential Applications, Plant Stem Cell Rejuvenation, Plant Stem Cells: Human Therapeutics, Stem Cell Therapies, Cellular Therapies, Advanced Gene Therapeutics, Molecular basis of epigenetics, Cancer Therapies, Nano-Therapy, Bioengineering Therapeutics, Clinical Trials and Research in Cell and Gene Therapies, Regulatory and Ethical Issues of Therapies.

The conference was greeted by the conference Moderator: Dr. Andrei LaikhterChemgenes Corporation, USA. The support was extended by the Keynote Speaker: Dr. James Koropatnic, Lawson Health Research Institute and Western University; Dr. Anelia AtanassovaBioGlobaX Inc., CanadaDr. Noriyuki KasaharaUniversity of Miami, USA; Dr. Robert Hawkins, The Christie Hospital and University of Manchester, UK and Dr. Paul L. Hermonat, Central Arkansas Veterans Healthcare System, USA

OMICS International acknowledges the support of below Chairs and Co-chairs with whom we were able to run the scientific sessions smoothly it included: Dr. Ajan ReginaldCell Therapy Limited, UKDr. Andrei LaikhterChemgenes Corporation, USADr. Vasiliki KalodimouIASO Maternity Hospital, GreeceDr. Geeta ShroffNutech Medicworld, India;Dr. Nady GolestanehGeorgetown University School of Medicine, USADr. James KoropatnickLawson Health Research Institute and Western University, CanadaDr. Robert HawkinsChristie Hospital and University of Manchester, UK.

This 4th International Conference and Exhibition on Cell & Gene Therapy was uplifted with more than 32 oral presentations by researchers, scientists, professors, industry delegates and more than 15 poster participants around the globe. OMICS International has taken the privilege of felicitating Cell Therapy-2015 Organizing Committee Members, Editorial Board Members of the supported Journals and Keynote Speakers who supported for the success of this event.

With the enormous feedback from the participants and supporters 4th International Conference and Exhibition on Cell & Gene Therapy, OMICS International Conferences is glad to announce its 5th International Conference and Exhibition on Cell & Gene Therapy (Cell Therapy-2016) event from May 19-21, 2016 at San Antonio, USA


Past Reports  Gallery  

Cell Therapy-2014
Cell Therapy-2014 Report

3rd International Conference and Exhibition on Cell & Gene Therapy was held duringOctober 27-29, 2014 at Las Vegas, USA with a theme “Uncover the potential that lies within the cell” brought together the International blend of people from Evolving Cell & Gene Therapies making it the largest endeavour from OMICS Group. All the papers presented at this conference were published in special issue of Journal of Stem Cell Research & Therapy.

Cell Therapy-2014 opened up new vistas and fostered collaborations in the industry and academia.

The conference was embarked with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were;

Dr. Paul L Hermonat, Central Arkansas Veterans Healthcare System, USA
Dr. Peter J Quesenberry, The Warren Alpert Medical School of Brown University, USA
Dr. Rafael Gonzalez, DaVinci Biosciences, LLC USA
Dr. Paul J Davis, Albany Medical College, USA
Dr. Stephen Lin, Thermo Fisher Scientifi c, USA

OMICS Group has taken the privilege of felicitating Cell Therapy-2014 Organizing Committee, Editorial Board Members, Keynote Speakers and business delegates who supported for the success of this event.

OMICS Group, on behalf of the conference, congratulates the Best Poster awardees for their outstanding performance in the field of Cell & Gene and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours. Our warm gratitude to our sponsors exhibitors & media partners for associating with the conference.


Past Reports  Gallery  

Cell Therapy-2013

2nd International Conference and Exhibition on Cell & Gene Therapy was held duringOctober 23-25 2013, at Orlando-FL, USA with a theme “Innovative Strategies in Cell & Gene Therapies” brought together the International blend of people from Evolving Cell & Gene Therapies making it the largest endeavour from OMICS Group. All the papers presented at this conference were published in special issue of Journal of Stem Cell Research & Therapy.

Cell Therapy-2013 opened up new vistas and fostered collaborations in the industry and academia.

The conference was embarked with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were;

Dr. Paul L. Hermonat, Central Arkansas Veterans Healthcare System, USA
Dr. Valentin Fulga, Hemostemix, Canada
Dr. Sean M. Sullivan, Vical Inc., USA
Dr. Leigh Mack, University of Oxford, UK

OMICS Group has taken the privilege of felicitating Cell Therapy-2013 Organizing Committee, Editorial Board Members, Keynote Speakers and business delegates who supported for the success of this event.

OMICS Group, on behalf of the conference, congratulates the Best Poster awardees for their outstanding performance in the field of Cell & Gene and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours. Our warm gratitude to our sponsors exhibitors & media partners for associating with the conference.

Following on the heels of this successful event we are excited to announce 3rdInternational Conference and Exhibition on Cell & Gene Therapy to be held duringOctober 27-29, 2014 at Las Vegas, USA with a theme Uncover the potential that lies within the cell” and wish that with your overwhelming support for Cell Therapy-2014 will become an outstanding event.


Past Reports  Gallery  

Cell Therapy-2012

Past Reports  Gallery  

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date May 19-21, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2 Day 3
Poster Opportunity Available

Media Partners

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
celltherapy@omicsgroup.com
Sponsors / Exhibiting / Advertising.
celltherapy@conferenceseries.net
General Queries.
celltherapy@conferenceseries.com

View Proceedings of Previous Conferences

Cell Therapy 2015 Proceedings
Cell Therapy 2014 Proceedings
Cell Therapy 2013 Proceedings
Cell Therapy 2012 Proceedings
Authorization Policy

By registering for the conference you grant permission to Conferenceseries LLC to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.